

Roche To Divest Legacy Genentech Facility in Vacaville, California, as Part of Long-term Strategy to Evolve Manufacturing Capabilities

Basel, 31 May 2023

Roche announced today that it plans to divest its legacy Genentech manufacturing facility in Vacaville, California, USA, as part of a broader strategy to evolve its manufacturing capabilities in line with future pipeline requirements. The company will initiate a process of finding a suitable buyer for the site and a decision will be announced in due course.

“The Vacaville site has a 25-year legacy of producing innovative medicines for millions of patients around the world,” said Susanne Hundsbaek-Pedersen, Global Head of Pharma Technical Operations, Roche. “We aim to find a buyer who shares our values and respects the contributions and expertise of our colleagues at the facility. At this time, there is no impact to operations, or to our employees, and we are committed to treating our colleagues in Vacaville with care and compassion throughout this process.”

The Vacaville site is one of the oldest in the Roche network and specialises in large-scale production of biologics medicines. Large scale production remains important in the delivery of Roche’s marketed medicines and will be supported out of one of our newer facilities. In addition, our pipeline continues to diversify across a range of modalities, from monoclonal and bispecific antibodies to cell therapies and personalised cancer vaccines. This requires production of increasingly individualised medicines for defined patient populations rather than large scale production of biologics.

About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations

Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD

Phone: +41 79 407 72 58

Nathalie Altermatt

Phone: +41 79 771 05 25

Karsten Kleine

Phone: +41 79 461 86 83

Nina Mähltitz

Phone: +41 79 327 54 74

Kirti Pandey

Phone: +49 172 6367262

Sileia Urech

Phone: +41 79 935 81 48

Genentech Media Relations

Phone: +1 (650) 467-6800 / [online media inquiries](#)

Heather Gloe

Phone: +1 415-518-9583

Susan Willson

Phone: + 1 415-509-8202